Optic Nerve Diseases Market Size to Grow at a CAGR of 3.46% during 2024-2034, Impelled by Advancements in Early Detection

Optic Nerve Diseases Market Outlook 2024-2034:

The optic nerve diseases market size is expected to exhibit a CAGR of 3.46% during 2024-2034. The market is driven by laser therapy to improve the drainage of fluid from the eyes, repair damaged nerve fibers, and reduce intraocular pressure. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Optic Nerve Diseases Market 

Advances in early detection and diagnostic technologies are playing a crucial role in driving the growth of the optic nerve diseases market, which includes conditions such as optic neuritis, glaucoma, and optic neuropathies. The development of cutting-edge diagnostic tools is enabling clinicians to detect optic nerve diseases at their earliest stages, even before noticeable symptoms appear. One of the most significant advancements is in imaging technologies, particularly optical coherence tomography (OCT) and fundus photography. OCT allows for high-resolution, non-invasive cross-sectional imaging of the retina and optic nerve head, providing detailed views of nerve fiber layer thickness and other critical parameters that can signal early-stage glaucoma or optic neuropathies. Additionally, OCT angiography, which allows for detailed imaging of the blood vessels in the retina, is becoming increasingly important in detecting vascular-related optic nerve disorders. These imaging technologies not only aid in early diagnosis but also assist in monitoring disease progression and treatment response, enabling more personalized and effective management strategies. Genetic testing has also seen considerable progress, offering the potential for early detection of hereditary optic nerve diseases, such as Leber hereditary optic neuropathy (LHON) or autosomal dominant optic atrophy (ADOA). Identifying genetic mutations associated with these diseases can help in offering targeted therapies and counseling for at-risk individuals. Furthermore, early intervention with medical treatments, such as neuroprotective drugs, and surgical interventions like optic nerve decompression have shown promise in halting or slowing disease progression. As technology continues to evolve, the optic nerve diseases market is expected to expand further, with improved diagnostic capabilities driving better outcomes and more targeted therapies for patients.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is playing a crucial role in driving the expansion of the optic nerve diseases market. One of the most promising areas is the development of neuroprotective drugs aimed at preserving optic nerve function and preventing further damage. For example, in glaucoma management, therapies such as Rho kinase inhibitors and neuroprotective agents are being explored to protect retinal ganglion cells, slow the degeneration of optic nerve fibers, and preserve vision. In conditions like optic neuritis, corticosteroids have traditionally been used to reduce inflammation, but ongoing research is focusing on more targeted immunomodulatory treatments to reduce the frequency of relapses and improve long-term outcomes. Gene therapy is another revolutionary approach showing promise in treating hereditary optic nerve diseases such as LHON and ADOA. For instance, gene therapies aimed at delivering healthy copies of defective genes directly to retinal cells are undergoing clinical trials, potentially offering curative treatments for these inherited conditions. Moreover, pharmacological agents designed to enhance mitochondrial function are being studied for their potential to address the underlying cellular dysfunction seen in diseases like LHON. In addition to these innovations, advancements in stem cell therapy and regenerative medicine are showing potential to repair damaged optic nerve tissue and restore vision. The growing availability of these novel therapies, alongside improved diagnostic technologies, is driving greater market demand for effective treatments and fostering greater investment in optic nerve disease research.

Marketed Therapies in Optic Nerve Diseases Market

Rocklatan (Latanoprost/netarsudil): Alcon

Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is used to reduce increased intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension. Rocklatan is a liquid solution containing two active medicines, netarsudil and latanoprost. Netarsudil belongs to a class of drugs known as Rho kinase inhibitors. Latanoprost belongs to a class of drugs known as prostaglandin analogs. Together, these drugs lower eye pressure and lessen the risk of problems caused by high eye pressure.

Durysta (Bimatoprost sustained release): AbbVie

Durysta (bimatoprost) is often used to lower elevated eye pressure in persons suffering from open-angle glaucoma or ocular hypertension. Durysta belongs to a class of medications known as prostaglandin analogs. People with glaucoma or ocular hypertension have a high IOP, which raises the risk of vision loss and nerve damage in the eyes. Durysta is an implant administered into the eye by a healthcare professional. It works by allowing the fluid in the eye to drain, hence lowering IOP.

Lumigan (Bimatoprost): AbbVie

Lumigan (Bimatoprost) is used to reduce excessive IOP in people with open-angle glaucoma or ocular hypertension. Bimatoprost mimics the effects of prostamides, particularly prostaglandin F2α. The drug slightly promotes aqueous humor outflow, reducing high intraocular pressure and lowering the risk of optic nerve injury. Bimatoprost is considered to lower IOP in people by increasing the outflow of aqueous humor via the trabecular meshwork and uveoscleral channels. It produces these benefits by reducing tonographic resistance to aqueous humor outflow.

Uplizna (Inebilizumab): Horizon Therapeutics plc 

Uplizna (Inebilizumab) is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients who have anti-aquaporin-4 (AQP4) antibodies. Uplizna attaches to CD19, a protein found on B cells, and eliminates them from the body. In NMOSD, B cells make antibodies that target AQP4, a protein required for nerve cell activity. Uplizna protects nerve cells and alleviates symptoms by lowering the quantity of B cells. Uplizna can lower the likelihood of NMOSD attacks, disability score worsening, and the frequency of hospitalizations due to NMOSD.

Enspryng (Satralizumab): Chugai Pharmaceuticals/Roche

Enspryng (Satralizumab), developed by Chugai Pharmaceutical and Roche, is approved for the treatment of NMOSD in adult patients with AQP4 antibodies. Enspryng uses a unique recycling antibody technology in which satralizumab binds to interleukin-6 (IL-6) receptors in a pH-dependent manner. Satralizumab is a humanized monoclonal antibody that works against human IL-6 receptors. It binds to both soluble and membrane-bound IL-6 receptors, preventing the signaling cascade and subsequent pro-inflammatory effects caused by its binding to endogenous IL-6.

Emerging Therapies in Optic Nerve Diseases Market

NCX 470: NicOx 

NCX 470 is an innovative nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent IOP-lowering properties of NO and prostaglandin analogs (PGAs). NCX 470 combines Nicox's proprietary NO-donating research platform with bimatoprost in a single molecule. NCX 470 is intended to deliver bimatoprost and NO into the eye, lowering IOP via two distinct mechanisms in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that regulates IOP by activating soluble guanylate cyclase (sGC). NO increases IOP-lowering efficacy by improving aqueous humor outflow from the eye through a mechanism of action distinct from that of PGAs.

STN1012600: Santen Pharmaceutical

STN1012600 is a dual agonist of the FP and EP3 receptors, using sepetaprost as its active ingredient, which was developed and manufactured by Ono Pharmaceutical Co., Ltd. STN1012600 is a prostaglandin derivative used to treat glaucoma and ocular hypertension. It contains 0.002% sepetaprost and uses a unique method of action to reduce intraocular pressure.

QLS-101: Qlaris Bio

QLS-101 is an innovative topical eyedrop that modulates ATP-sensitive potassium (KATP) channels. QLS-101 significantly reduces episcleral venous pressure (EVP), an essential indicator of IOP, or fluid pressure in the eye, which can be high in glaucoma patients. QLS-101 has the potential to be an effective monotherapy or additive therapy for lowering IOP in primary open angle glaucoma (POAG). It may also serve as a new treatment paradigm for normal-tension glaucoma and patients with Sturge-Weber syndrome.

Ravulizumab: Alexion AstraZeneca Rare Disease

Ravulizumab is a humanized monoclonal antibody that suppresses the terminal complement pathway by binding to the human terminal complement protein C5. Ravulizumab inhibits the cleavage of C5 into C5a and C5b, which are pro-inflammatory and pro-thrombotic anaphylatoxins. This stops the chain reaction that leads to the degradation of the postsynaptic neuromuscular junction membrane, which can cause muscle weakness.

Detailed list of emerging therapies in Optic Nerve Diseases is provided in the final report.

Leading Companies in the Optic Nerve Diseases Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global optic nerve diseases market, several leading companies are at the forefront of developing integrated platforms to enhance the management of optic nerve diseases. Some of the major players include Chugai Pharmaceuticals, Roche, and Horizon Therapeutics plc. These companies are driving innovation in the optic nerve diseases market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

​In January 2024, Horizon Therapeutics plc declared that Health Canada had authorized UPLIZNA (inebilizumab for injectable) as a monotherapy for the treatment of adult AQP4-IgG+ patients with NMOSD.

In June 2021, Chugai Pharmaceutical Co., Ltd. announced that Roche had been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng (satralizumab), created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with AQP4-IgG seropositive NMOSD, as a monotherapy or in combination with immunosuppressive therapy.

Key Players in Optic Nerve Diseases Market:

The key players in the Optic Nerve Diseases market who are in different phases of developing different therapies are Chugai Pharmaceuticals, Roche, AbbVie, Alcon, Horizon Therapeutics plc, NicOx, Santen Pharmaceutical, Qlaris Bio, Alexion AstraZeneca Rare Disease, and Others.

Regional Analysis:

The major markets for optic nerve diseases include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for optic nerve diseases while also representing the biggest market for its treatment. This can be attributed to the rising demand for advanced diagnostic technologies, such as OCT and AI-powered imaging tools, which allow for earlier detection of optic nerve damage.

Moreover, another significant driver is the growing availability of innovative therapies, including neuroprotective drugs, gene therapies, and neurostimulation treatments. Gene therapy for hereditary optic diseases, such as LHON, has gained significant attention, with clinical trials showing promising results in restoring vision. These advancements are driving the need for specialized care, creating opportunities for the development of new pharmacological treatments that address the underlying causes of optic nerve damage.

Besides this, the regulatory environment, including incentives like orphan drug status for rare optic nerve diseases, encourages investment in novel therapies. Combined with increasing public awareness and the aging population, these factors are driving the optic nerve diseases market, leading to greater demand for both diagnostic and therapeutic innovations​.

Recent Developments in Optic Nerve Diseases Market:

• In December 2024, Nicox SA stated that its Denali Phase 3 trial, which is examining the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension, had reached full enrollment in China and screening had been completed.
• In September 2024, Santen Pharmaceutical Co., Ltd. announced that it had filed an application for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action to lower IOP.
• In March 2024, Alexion AstraZeneca Rare Disease announced that ULTOMIRIS (ravulizumab-cwvz) had been approved in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with AQP4 antibody-positive (Ab+) neuromyelitis optica spectrum disorder.

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the optic nerve diseases market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the optic nerve diseases market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current optic nerve diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800